Ecopladib is primarily researched for its potential therapeutic applications, particularly in the field of inflammatory diseases. It functions as a selective inhibitor of cytosolic phospholipase A2 alpha (cPLA2α), an enzyme involved in the production of pro-inflammatory mediators. By inhibiting this enzyme, it may help reduce inflammation and associated symptoms in conditions such as rheumatoid arthritis, asthma, and other chronic inflammatory disorders. Its application is currently under investigation in preclinical and clinical studies to evaluate its efficacy and safety as a treatment option for these diseases.